Astec LifeSciences Future Growth

Future criteria checks 5/6

Astec LifeSciences se prevé un crecimiento anual de los beneficios y los ingresos de 112.2% y 35.8% respectivamente. Se prevé que el BPA sea de grow en 112.2% al año. Se prevé que la rentabilidad de los fondos propios sea de 16.6% en 3 años.

Key information

112.2%

Earnings growth rate

112.2%

EPS growth rate

Chemicals earnings growth	19.7%
Revenue growth rate	35.8%
Future return on equity	16.6%
Analyst coverage	Low
Last updated	02 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BSE:533138 - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2026	9,112	931	N/A	N/A	2
3/31/2025	6,902	579	N/A	N/A	2
3/31/2024	4,300	-425	N/A	N/A	1
12/31/2023	4,317	-509	N/A	N/A	N/A
9/30/2023	4,981	-258	-1,580	101	N/A
6/30/2023	5,871	60	N/A	N/A	N/A
3/31/2023	6,285	256	-426	747	N/A
12/31/2022	7,735	736	N/A	N/A	N/A
9/30/2022	8,297	975	-448	351	N/A
6/30/2022	7,325	883	N/A	N/A	N/A
3/31/2022	6,769	899	-804	236	N/A
12/31/2021	5,803	708	N/A	N/A	N/A
9/30/2021	5,230	531	-800	483	N/A
6/30/2021	5,754	619	N/A	N/A	N/A
3/31/2021	5,587	650	-1,107	-82	N/A
12/31/2020	5,698	723	N/A	N/A	N/A
9/30/2020	5,786	774	1,190	1,885	N/A
6/30/2020	5,639	648	N/A	N/A	N/A
3/31/2020	5,287	475	1,231	1,684	N/A
12/31/2019	4,844	291	N/A	N/A	N/A
9/30/2019	4,781	269	-420	32	N/A
6/30/2019	4,507	331	N/A	N/A	N/A
3/31/2019	4,382	357	-375	153	N/A
12/31/2018	4,246	402	N/A	N/A	N/A
9/30/2018	3,781	374	N/A	N/A	N/A
6/30/2018	3,611	325	N/A	N/A	N/A
3/31/2018	3,676	349	150	647	N/A
12/31/2017	3,254	212	N/A	N/A	N/A
9/30/2017	3,119	148	N/A	N/A	N/A
6/30/2017	3,008	192	N/A	N/A	N/A
3/31/2017	2,987	191	N/A	192	N/A
12/31/2016	3,167	-29	N/A	N/A	N/A
9/30/2016	2,865	-114	N/A	N/A	N/A
6/30/2016	2,643	-206	N/A	N/A	N/A
3/31/2016	2,330	50	N/A	-125	N/A
12/31/2015	2,629	-115	N/A	N/A	N/A
9/30/2015	2,777	61	N/A	N/A	N/A
6/30/2015	2,728	84	N/A	N/A	N/A
3/31/2015	2,669	148	N/A	75	N/A
12/31/2014	2,212	131	N/A	N/A	N/A
9/30/2014	2,147	127	N/A	N/A	N/A
6/30/2014	2,156	96	N/A	N/A	N/A
3/31/2014	2,070	87	N/A	146	N/A
12/31/2013	2,179	97	N/A	N/A	N/A
9/30/2013	2,076	76	N/A	N/A	N/A
6/30/2013	1,849	72	N/A	N/A	N/A

Analyst Future Growth Forecasts

Ingresos vs. tasa de ahorro: 533138 se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (6.7%).

Beneficios frente mercado: 533138 se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: 533138 se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: 533138Se prevé que los ingresos de la empresa (35.8% al año) crezcan más deprisa que los del mercado Indian (10.5% al año).

Ingresos de alto crecimiento: 533138Se prevé que los ingresos de la empresa (35.8% al año) crezcan más deprisa que 20% al año.

Earnings per Share Growth Forecasts

Future Return on Equity

Futura rentabilidad financiera (ROE): 533138Se prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (16.6%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Astec LifeSciences Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased by 9.3% to ₹1,205

Price target decreased to ₹1,923

Price target increased to ₹2,132

Price target increased to ₹1,869

Price target increased to ₹1,508

Price target increased to ₹1,386

Recent updates

Price target decreased by 9.3% to ₹1,205

Third quarter 2024 earnings released: ₹12.41 loss per share (vs ₹0.43 profit in 3Q 2023)

Astec LifeSciences Limited to Report Q3, 2024 Results on Jan 25, 2024

Second quarter 2024 earnings released: ₹6.85 loss per share (vs ₹9.34 profit in 2Q 2023)

Astec LifeSciences Limited to Report Q2, 2024 Results on Oct 27, 2023

Astec LifeSciences Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Astec LifeSciences Limited to Report Q1, 2024 Results on Jul 27, 2023

Upcoming dividend of ₹1.50 per share at 0.1% yield

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Non-Executive Non-Independent Director recently sold ₹4.8m worth of stock

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023, Payable by August 1, 2023

Full year 2023 earnings released: EPS: ₹13.04 (vs ₹45.87 in FY 2022)

Investor sentiment improves as stock rises 26%

Third quarter 2023 earnings released: EPS: ₹0.43 (vs ₹12.63 in 3Q 2022)

Astec LifeSciences Limited to Report Q3, 2023 Results on Jan 30, 2023

Price target decreased to ₹1,923

High number of new directors

Second quarter 2023 earnings released: EPS: ₹9.34 (vs ₹4.63 in 2Q 2022)

Astec Lifesciences Limited Announces Appointment of Mr. Madhur Gundecha as the Chief Financial Officer

Astec LifeSciences Limited to Report Q2, 2023 Results on Oct 28, 2022

Investor sentiment improved over the past week

Astec LifeSciences Limited Announces the Resignation of Saurav Bhala as Chief Financial Officer

Price target increased to ₹2,132

High number of new directors

Astec Lifesciences Limited Appoints Burjis Godrej as an Additional, Non-Executive, Non- Independent Director

Astec LifeSciences Limited to Report Q1, 2023 Results on Jul 25, 2022

Upcoming dividend of ₹1.50 per share

Full year 2022 earnings: Revenues exceed analyst expectations

Price target increased to ₹1,869

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Astec LifeSciences Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

MD & Director recently bought ₹37m worth of stock

Astec LifeSciences Limited Announces Cessation of Ashok Hiremath as the Managing Director of the Company

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹1.5m worth of stock

Non-Executive Non-Independent Director recently bought ₹3.5m worth of stock

Investor sentiment deteriorated over the past week

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insider recently sold ₹1.5m worth of stock

Investor sentiment improved over the past week

Insider recently sold ₹2.4m worth of stock

Price target increased to ₹1,508

Price target increased to ₹1,386

Upcoming dividend of ₹1.50 per share

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Whole Time Director recently sold ₹2.9m worth of stock

Investor sentiment improved over the past week

MD & Director recently sold ₹240m worth of stock

Full year 2021 earnings released: EPS ₹33.23 (vs ₹24.29 in FY 2020)

Astec Lifesciences Limited Recommends Final Dividend for the Year Ended March 31, 2021, Payable on August 6, 2021

Price target decreased to ₹1,221

Astec LifeSciences Limited to Report Q3, 2021 Results on Jan 25, 2021

New 90-day high: ₹1,194

MD & Director recently sold ₹440m worth of stock

New 90-day low: ₹986

MD & Director recently sold ₹527m worth of stock

First half earnings released

MD & Director recently sold ₹57m worth of stock

MD & Director recently sold ₹15.2m worth of stock

New 90-day high: ₹1,271

MD & Director recently sold ₹11.3m worth of stock

New 90-day high - ₹1,254

MD & Director recently sold ₹32.9m worth of stock

Astec LifeSciences Limited to Report Q1, 2021 Results on Jul 22, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity